Categorized | Investing

Quality Healthcare Stock Options

Share Button

Healthcare StockThe huge demand for healthcare stock, and in particular, pharmaceuticals, has dipped recently. This is due in part to the lack of recent major drug breakthroughs. However, with Wall Street still showing signs of its own robust health, there are several pharmaceuticals that bear a second look.

Healthcare Stock on the Rise

AstraZeneca is a London based pharmaceutical company that operates in 100 countries. They manufacture drugs for most of the major diseases, such as heart disease, cancer, and neuro-disease. Because they have lost the exclusive rights to many of their key brands, they have seen a 7% dip in group sales. They are, however, set to begin ratcheting up their sales again, although the results may take time to bear fruition. This is because at the moment, they have 71 major projects in the developmental phase. However, they do have 13 projects either approved, launched, or filed. The company is reorganizing with a new strategy for returning to growth. This should help the patient investor reap great rewards in the future.

Tenet Healthcare Corp.

This company’s stock has been rising in huge increments since 2011. Tenet Healthcare is a health services company owning and operating hospitals and care centers. In fact, in 2011, they bought 15 outpatient centers. Their stock was earning 52-cents a share back then, and in 2012, they were earning $1.73 per share. By 2014, the stocks are estimated to earn $3.51 per share. Investors may expect to earn a profit with these stocks, and those who are in it for the long run may expect to earn even greater rewards.

There are other top-performing options available to investors. United Health Group and Cigna Corporation top the list with A-plus ratings. While investments in healthcare may not appear to be reaping great rewards at the moment, a little research and patience should help investors to unearth a few diamonds.

Stay up to date on healthcare stock by getting on our FREE eMail list!

This post was written by:

- who has written 2169 posts on StockRockandRoll.

Contact the author

Comments are closed.

© 2020 MJ Capital, LLC | All rights reserved